weightlossdrugs

#BinancePick
Eli Lilly Earnings Preview: Can Mounjaro and Zepbound Sustain Their Explosive Growth?

Sometimes, a breakthrough changes not just an industry, but the scale of an entire business.

Eli Lilly ($LLY ) reports Q3 earnings on October 29, and investors will be watching whether its blockbuster medicines can keep delivering extraordinary growth.

The latest results are striking. In Q2 2026, Lilly generated $23 billion in revenue, up 48% year over year, driven primarily by Mounjaro and Zepbound.

Mounjaro revenue reached approximately $9.9 billion, while Zepbound generated $4.9 billion. Together, these medicines represented roughly 65% of Lilly's revenue during the first half of 2026.

But explosive demand is only half the story.

Lilly raised its 2026 revenue guidance to $85 billion to $87 billion. Yet lower realized drug prices, manufacturing expansion, and intensifying competition could influence how much of that growth reaches the bottom line.

Another catalyst is the pipeline. Lilly's investigational next-generation obesity medicine, retatrutide, could strengthen its longer-term growth prospects, although clinical promise does not guarantee commercial success.

My outlook: Strong prescription demand, resilient sales volumes, and confident guidance could support a bullish reaction. However, weaker pricing, disappointing forecasts, or concerns about competition could trigger volatility, even if revenue beats expectations.

The crucial question is whether Lilly can turn today's extraordinary demand into durable earnings growth.

In healthcare, a blockbuster creates opportunity. Consistent execution determines its lasting value.

Will Mounjaro and Zepbound keep powering Lilly higher, or are investor expectations becoming too demanding?

For educational purposes only. Not financial advice.

#EliLilly #WeightLossDrugs #GrowWithSAC #EarningsSeason
$LLY